[Frequent ventricular tachycardias: antiarrhythmic drug treatment or catheter ablation?]
Hildegard Tanner1, Gerhard Hindricks, Hans Kottkamp
1Kardiologie - Abteilung für Rhythmologie/Elektrophysiologie, Universitat Leipzig-Herzzentrum.
Insights
Antiarrhythmic drugs and catheter ablation are treatment options for patients with implantable cardioverter-defibrillators (ICDs) to manage ventricular arrhythmias (VTs). Treatment choice depends on individual patient factors, balancing efficacy with potential adverse effects.
Area of Science:
- Electrophysiology
- Cardiology
- Pharmacology
Context:
- Over 50% of patients with implantable cardioverter-defibrillators (ICDs) use antiarrhythmic drugs.
- These drugs aim to reduce ventricular tachycardias (VTs) and ventricular fibrillation (VF) episodes, decreasing ICD therapies and shocks.
- Potential benefits include improved quality of life and extended ICD battery life.
Purpose:
- To evaluate the role of antiarrhythmic drugs and catheter ablation in managing ventricular arrhythmias in ICD patients.
- To discuss the efficacy and adverse effects of antiarrhythmic drugs like amiodarone, sotalol, and azimilide.
- To explore catheter ablation as an alternative or adjunctive therapy for refractory VTs.
Summary:
- Antiarrhythmic drugs can reduce ICD shocks and improve VT cycle length, but may increase defibrillation thresholds or cause detection failure.
- Trials show amiodarone, sotalol, and azimilide reduce ICD shocks in structural heart disease patients.
- Catheter ablation is considered when drugs are ineffective or cause side effects, particularly for unstable VTs.
Impact:
- Individualized treatment selection is crucial, considering patient-specific clinical and electrophysiological features.
- VT ablation is increasingly effective but often serves as adjunctive therapy due to recurrence and new VT development.
- Further research may clarify the optimal role of ablation as a primary treatment.
Abstract:
Antiarrhythmic drugs are used in at least 50% of patients who received an implantable cardioverter defibrillator (ICD). The potential indications for antiarrhythmic drug treatments in patients with an ICD are generally the following: reduction of the number of ventricular tachycardias (VTs) or episodes of ventricular fibrillation and therefore reduction of the number of ICD therapies, most importantly, the number of disabling ICD shocks. Accordingly, the quality of life should be improved and the battery life of the ICD extended. Moreover, antiarrhythmic drugs have the potential to increase the tachycardia cycle length to allow termination of VTs by antitachycardia pacing and reduction of the number of syncopes. In addition, supraventricular arrhythmias can be prevented or their rate controlled. Recently published or reported trials have shown the efficacy of amiodarone, sotalol and azimilide to significantly reduce the number of appropriate and inappropriate ICD shocks in patients with structural heart disease. However, the use of antiarrhythmic drugs may also have adverse effects: an increase in the defibrillation threshold, an excessive increase in the VT cycle length leading to detection failure. In this situation and when antiarrhythmic drugs are ineffective or have to be stopped because of serious side effects, catheter ablation of both monomorphic stable and pleomorphic and/or unstable VTs using modern electroanatomic mapping systems should be considered. The choice of antiarrhythmic drug treatment and the need for catheter ablation in ICD patients with frequent VTs should be individually tailored to specific clinical and electrophysiological features including the frequency, the rate, and the clinical presentation of the ventricular arrhythmia. Although VT mapping and ablation is becoming increasingly practical and efficacious, ablation of VT is mostly done as an adjunctive therapy in patients with structural heart disease and ICD experiencing multiple shocks, because the recurrence and especially the occurrence of "new" VTs after primarily successful ablation with time and disease progression have precluded a widespread use of catheter ablation as primary treatment.
Related Concept Videos
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Dysrhythmias VI: Management of Dysrhythmias
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Mechanism of Cardiac Arrhythmias
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers


